Product

USP’s

Salion‘s LATERAL FLOW TESTS

Point of care testing  has many advantages over invasive procedures, such as:

  • Easy to follow instructions
  • Quick & comfortable test procedure
  • Reliable result
  • At-home service requiring no hospital or medical practice visit
  • Reduced stress for patients, medical staff & relatives due to comfort of at home use.

=> Improved Quality of Life 

  • Convenient and advantageous for use in child care
  • Cost effective
  • Low production costs
  • Lateral flow tests “for the masses”
  • Multiple fields of application in future
  • Patent successfully registered in relevant markets worldwide!

A qualitative test of kynurenine concentration in saliva which can be run frequently (e.g. once a week) could substantially improve patients’ quality of life/treatment experience.


Knowing whether the concentration level of kynurenine is nearing a critical area can help by:

– Reducing costs due to less hospitalisation and less medication being required.

– Lower dosage of medication also means fewer side effects and greater patient comfort.

– Fewer hospitalizations mean fewer invasive procedures. 

– Patients would be afforded a greater level of independence, e.g. They can go on holidays.

– Patient mental health would be improved due to the comfortable procedure contributing to reduced stress levels

Cost effectiveness

According to the DSO (Deutsche Stiftung für Organtransplantation) about 40 thousand patients in Germany are currently receiving aftercare having had an organ transplant.

Costs can be substantially  reduced by improving transplant survival rate as well as any reduction in prescription of  immunosuppressive medication.

For example, the costs for ten years of monitoring with our test is equivalent to the costs of 4 to 6 weeks of dialysis. The treatment of an episode of transplant rejection amounts to approximately 7100 Euros.

Our test will  considerably reduce the cost of care per patient. 

 Proof of concept

Fraunhofer Institut in Postdam (IZI-BB) as well as Prof. Deigner´s group at the University of Villingen-Schwenningen have tested and confirmed the capability of our test. 

The principle behind lateral flow assay (LFA) is uncomplicated: a liquid sample containing the analyte of interest moves without the assistance of external forces (through capillary action) through a polymeric strip, on which a molecule that can interact with the analyte is attached.

In our case the liquid sample is saliva, the analyte of interest is kynurenine. The molecule to which kynurenine interacts on the strip is a monoclonal antibody.

Monoclonal antibodies are a type of protein made in the laboratory. They can bind to a substance in the body. A monoclonal antibody is made so that it binds to only one substance.

Our lateral flow assay is based on monoclonal antibody against kynurenine. It reacts to the presence of kynurenine by latching onto it. Through this connection a change of colour in the test line is induced, in principle for patients it is identifiable from the concept of a pregnancy or urine test. Lateral flow assay represents a well-established and appropriate technology among rapid assays because of its low cost and user friendliness. Our test has been tested successfully in patients who have received kidney, heart, pancreas, small intestine and cornea transplants. Its operability was also demonstrated in the transplant of an extremity. We are convinced that our results can be applied to  liver, lung and facial tissue transplants as well.